10.59

8.28% +0.81

After Hours: 10.59

Shattuck Labs Inc (STTK)

Overview News Price History Option Chain Discussions Forecast

Shattuck Labs Inc stock is currently priced at $10.59, with a 24-hour trading volume of 381.46K. It has seen a +8.28% increased in the last 24 hours and a +19.66% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $9.71 pivot point. If it approaches the $10.38 resistance level, significant changes may occur.

Previous Close:

$9.78

Open:

$9.82

24h Volume:

381.46K

Market Cap:

$503.56M

Revenue:

$1.66M

Net Income/Loss:

$-87.30M

P/E Ratio:

-4.8802

EPS:

-2.17

Net Cash Flow:

$-81.64M

1W Performance:

+10.54%

1M Performance:

+19.66%

6M Performance:

+536.04%

1Y Performance:

+265.17%

1D Range:

$9.74

$10.64

52W Range:

$1.3301

$11.11

Shattuck Labs Inc Stock (STTK) Company Profile

Name

Shattuck Labs Inc

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

919 864 2700

Address

1018 West 11th Street, Suite 100, Austin

Employee

Twitter

Next Earnings Date

2024-05-07

Latest SEC Filings

STTK's Discussions on Twitter

Shattuck Labs Inc Stock (STTK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-31-22	Initiated	BTIG Research	Buy
Jun-01-22	Initiated	Citigroup	Buy
May-02-22	Initiated	H.C. Wainwright	Buy
Apr-14-21	Initiated	Berenberg	Buy
Jan-11-21	Initiated	Evercore ISI	Outperform
Nov-03-20	Initiated	Citigroup	Buy
Nov-03-20	Initiated	Cowen	Outperform
Nov-03-20	Initiated	Needham	Buy

View All

Shattuck Labs Inc Stock (STTK) Latest News

Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024

GlobeNewswire Inc.

Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire Inc.

Shattuck Labs Announces Participation in Upcoming March Conferences

GlobeNewswire Inc.

Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases

GlobeNewswire Inc.

Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Benzinga

Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire Inc.

Shattuck Labs Inc Stock (STTK) Financials Data

Shattuck Labs Inc (STTK) Revenue 2024

STTK reported a revenue (TTM) of $1.66 million for the quarter ending December 31, 2023, a -94.48% decline year-over-year.

Shattuck Labs Inc (STTK) Net Income 2024

STTK net income (TTM) was -$87.30 million for the quarter ending December 31, 2023, a +14.37% increase year-over-year.

Shattuck Labs Inc (STTK) Cash Flow 2024

STTK recorded a free cash flow (TTM) of -$81.64 million for the quarter ending December 31, 2023, a +23.07% increase year-over-year.

Shattuck Labs Inc (STTK) Earnings per Share 2024

STTK earnings per share (TTM) was -$2.05 for the quarter ending December 31, 2023, a +14.94% growth year-over-year.

Shattuck Labs Inc Stock (STTK) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Stout Stephen	See Remarks	Mar 06 '24	Sale	10.53	16,004	168,522	74,437
Neill Andrew R	Chief Financial Officer	Jan 10 '24	Sale	10.00	25,000	250,000	173,446

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian cancer. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was founded in 2016 and is headquartered in Austin, Texas.